Pulmonary toxicity in a patient with psoriasis receiving methotrexate therapy

Clinical and Experimental Dermatology

Volumn 25, Issue 1, 2000, Pages 24-27

  McKenna, K E ^a   Burrows, D ^b  

^a Royal Victoria Hospitals Trust   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; TRANSFER FACTOR;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; LUNG FUNCTION TEST; LUNG TOXICITY; PRIORITY JOURNAL; PSORIASIS;

ADULT; DERMATOLOGIC AGENTS; FEMALE; FOLIC ACID ANTAGONISTS; FORCED EXPIRATORY VOLUME; HUMANS; METHOTREXATE; PSORIASIS; RESPIRATION DISORDERS; VITAL CAPACITY;

EID: 0034003192     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2000.00564.x     Document Type: Article

References (21)

1. Hanno R, Gruber GG, Owen LG, Gallen JP. Methotrexate in psoriasis: a brief review of indications, usage, and complications of methotrexate therapy. / Am Acad Dermatol 1980;2: 171-4.
2. Ashton RE, Millward-Sadler GH, White JE. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. / Invest Dermatol 1982; 79: 229-32.
3. Zachariae H, Sogaard II. Methotrexate-induced liver cirrhosis: a follow-up. Dermatologica 1987; 175: 178-82.
4. Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hématologie toxicity due to methotrexate therapy. Arthritis Rheum 1989; 32: 1592-6.
5. Filip DJ, Logue GL, Harle TS ft al. Pulmonary and hepatic complications of methotrexate therapy of psoriasis. JAMA 1971:216:881-2.
6. From E. Methotrexate pneumonitis in a psoriatic. Br ] Dermatol 1975; 93: 107-10.
7. Sostman D, Matthay RA, Putman CE, Walker-Smith GJ. Methotrexate-induced pneumonitis. Medicine 1976; 55: 371-87.
8. Philips TJ, Jones DH, Baker H. Pulmonary complications following methotrexate therapy. / Am Acad Dermntol 1987; 16:373-5.
9. Kaplan RL, Waite DH. Progressive interstitial lung disease from prolonged methotrexate therapy. Arch Dermatol 1978; 114:1800-2.
10. Lewis WL, Walter JE Methotrexate-induced pulmonary fibrosis. Arch Dmnatol 1979; 115: 1169-70.
11. Bedrossian CWM, Miller WC, Luna MA. Methotrexateinduced diffuse interstitial pulmonary fibrosis. South Med 71979:72:313-8.
12. Acute Leukemia Group B. Acute lymphoblastic leukemia in children. Maintenance therapy with methotrexate administrated intermittently. / Am Med Assoc 1969; 207: 923-8.
13. Dickley BF, Myers AR. Pulmonary disease in polymyositisdermatomyositis. Sem Arthritis Rheum 1984; 14: 60-76.
14. Barrera P, Laan RFJM, van Kiel PLCM et al. Methotrexaterelated pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 434-9.
15. Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterol 1994; 107: 266-70.
16. Clarysse AM. Cathey WJ, Cartwright GE, Wintrobe MM. Pulmonary disease complicating intermittent therapy with methotrexate. ]AMA 1969; 209: 1861-4.
17. Akoun GM, Gauthier-Rahman S, Maynaud CM et al. Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologie cell-mediated mechanism. Chest 1987; 91: 96-9.
18. Drug and poison-induced pulmonary disease. In: Eraser RG. Pare JAP, Pare PD, Fraser RS, eds. Diagnosis of Disease of the Chest. Philadelphia: W.B. Saunders,1991:2433-4.
19. Carson C\V, Cannon GW, Egger MJ et al. Pulmonary disease during treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 1987; 16:186-95.
20. Searles G, McKendry RJR. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. / Rhewnatol 1987; 14:1164-1171.
21. Phillips TJ, Wallis PJ, Jones DH, Baker H. Pulmonary function in patients on long-term, low-dose methotrexate. Br] Dermatol 1986; 115: 657-662.